Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND ...

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Brazil

◆ Source

Read at boursorama.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Biophytis received approval from Brazil's ANVISA to begin the Phase 2 OBA clinical trial for its obesity drug BIO101, following prior regulatory endorsements in the US and Europe, enabling multi-regional clinical development.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech startup can now view Brazil as a reachable market for clinical development with easier regulatory access for obesity treatments. Multi-region approvals speed development timelines and broaden patient recruitment options for drugs like BIO101.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechregulatory-approvalclinical-trialobesitybiotechbrazil